

1. Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B, Bonnetain F. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. *BMJ Open*. 2016;6(6):e010696. Epub 2016/06/28. doi: 10.1136/bmjopen-2015-010696. PubMed PMID: 27342239; PMCID: 4932346.
2. Azan A, Caspers PJ, Bakker Schut TC, Roy S, Boutros C, Mateus C, Routier E, Besse B, Planchard D, Seck A, Kamsu-Kom N, Tomasic G, Koljenović S, Noordhoek Hegt V, Matthieu T, Lanoy E, Eggermont AM, Paci A, Robert C, Puppels GJ, Mir LM. A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. *Cancer Res*. 2016. PubMed PMID: 27836854.
3. Barral M, Auperin A, Hakime A, Cartier V, Tacher V, Otmazguine Y, Tselikas L, de Baere T, Deschamps F. Percutaneous Thermal Ablation of Breast Cancer Metastases in Oligometastatic Patients. *Cardiovasc Intervent Radiol*. 2016;39(6):885-93. Epub 2016/02/11. doi: 10.1007/s00270-016-1301-x. PubMed PMID: 26860716.
4. Bayar MA, Le Teuff G, Michiels S, Sargent DJ, Le Deley MC. New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study. *Stat Med*. 2016;35(19):3245-58. Epub 2016/03/31. doi: 10.1002/sim.6942. PubMed PMID: 27027783.
5. Benhamou S, Bonastre J, Groussard K, Radvanyi F, Allory Y, Leuret T. A prospective multicenter study on bladder cancer: the COBLAnCE cohort. *BMC Cancer*. 2016;16(1):837. Epub 2016/11/05. doi: 10.1186/s12885-016-2877-x. PubMed PMID: 27809812; PMCID: 5094141.
6. Billaux M, Borget I, Prognon P, Pineau J, Martelli N. Innovative medical devices and hospital decision making: a study comparing the views of hospital pharmacists and physicians. *Aust Health Rev*. 2016;40(3):257-61. Epub 2015/09/08. doi: 10.1071/AH15039. PubMed PMID: 26342894.
7. Blanchard P, Belkhir F, Temam S, El Khoury C, De Felice F, Casiraghi O, Patrikidou A, Mirghani H, Levy A, Even C, Gorphe P, Nguyen F, Janot F, Tao Y. Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis. *Eur Arch Otorhinolaryngol*. 2016. Epub 2016/12/10. doi: 10.1007/s00405-016-4419-1. PubMed PMID: 27933385.
8. Blanchard P, Briganti A, Bossi A. Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol* 2016;70:21-30. *European urology*. 2016;70(1):e15-6. Epub 2016/02/29. doi: 10.1016/j.eururo.2016.02.040. PubMed PMID: 26922406.
9. Blanchard P, El Khoury C, Temam S, Casiraghi O, Mirghani H, Levy A, Gorphe P, Even C, De Felice F, Nguyen F, Janot F, Tao Y. [Oral cavity cancers among young people: Clinical results and prognostic analysis]. *Cancer Radiother*. 2016;20(2):91-7. Epub 2016/03/13. doi: 10.1016/j.canrad.2015.09.013. PubMed PMID: 26969246.
10. Blanchard P, Faivre L, Lesaunier F, Salem N, Mesgouez-Nebout N, Deniau-Alexandre E, Rolland F, Ferrero JM, Houede N, Mourey L, Theodore C,

- Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Davin JL, Habibian M, Culine S, Laplanche A, Fizazi K. Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial. *International journal of radiation oncology, biology, physics*. 2016;94(1):85-92. Epub 2015/11/19. doi: 10.1016/j.ijrobp.2015.09.020. PubMed PMID: 26576711.
11. Blanchard P, Garden AS. Looking Beyond the Numbers: Highlighting the Challenges of Population-Based Studies in Cancer Research. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2016;34(19):2317-8. Epub 2016/04/27. doi: 10.1200/JCO.2015.66.0894. PubMed PMID: 27114596.
 12. Blanchard P, Ribassin-Majed L, Lee A, Pignon JP. Comment on "Chemoradiotherapy regimens for locoregionally advanced nasopharyngeal carcinoma: a Bayesian network meta-analysis", published in *Eur J Cancer* 51 (2015), 1570-1579. *European journal of cancer*. 2016;56:183-5. Epub 2016/01/13. doi: 10.1016/j.ejca.2015.10.067. PubMed PMID: 26755270.
 13. Blanchard P, Volk RJ, Ringash J, Peterson SK, Hutcheson KA, Frank SJ. Assessing head and neck cancer patient preferences and expectations: A systematic review. *Oral oncology*. 2016;62:44-53. Epub 2016/11/21. doi: 10.1016/j.oraloncology.2016.09.008. PubMed PMID: 27865371.
 14. Blanchard P, Wong AJ, Gunn GB, Garden AS, Mohamed AS, Rosenthal DI, Crutison J, Wu R, Zhang X, Zhu XR, Mohan R, Amin MV, Fuller CD, Frank SJ. Toward a model-based patient selection strategy for proton therapy: External validation of photon-derived normal tissue complication probability models in a head and neck proton therapy cohort. *Radiother Oncol*. 2016. Epub 2016/09/20. doi: 10.1016/j.radonc.2016.08.022. PubMed PMID: 27641784.
 15. Bluthgen MV, Boutros C, Fayard F, Remon J, Plancharde D, Besse B. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience. *Lung Cancer*. 2016;99:111-6. Epub 2016/08/28. doi: 10.1016/j.lungcan.2016.06.020. PubMed PMID: 27565923.
 16. Bossi A, Blanchard P. Hypofractionation for prostate cancer: a word of caution. *The Lancet Oncology*. 2016;17(4):406-7. Epub 2016/03/13. doi: 10.1016/S1470-2045(15)00626-9. PubMed PMID: 26968358.
 17. Boutros C, Tarhini A, Routier E, Lambotte O, Ladirat FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, Lanoy E, Texier M, Libenciuc C, Eggermont AM, Soria JC, Mateus C, Robert C. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. *Nat Rev Clin Oncol*. 2016;13:473-86. PubMed PMID: 27141885.
 18. Brambilla E, Le Teuff G, Marquet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le Chevalier T, Filipits M, Rosell R, Kratzke R, Popper H, Soria JC, Shepherd FA, Seymour L, Tsao MS. Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. *J Clin Oncol*. 2016;34:1223-30. PubMed PMID: 26834066.
 19. Brard C, Le Teuff G, Le Deley MC, Hampson LV. Bayesian survival analysis in clinical trials: What methods are used in practice? *Clinical trials*. 2016. Epub 2016/10/13. doi: 10.1177/1740774516673362. PubMed PMID: 27729499.
 20. Bredart A, Bodson S, Le Tourneau C, Flahault C, Bonnetain F, Beaudeau A, Coquan E, Dolbeault S, Paoletti X. Patients' perceived tolerance of side

- effects in phase I cancer clinical trials: A qualitative study. *European journal of cancer care*. 2016. Epub 2016/10/14. doi: 10.1111/ecc.12596. PubMed PMID: 27734561.
21. Burdett S, Rydzewska L, Tierney J, Fisher D, Parmar MK, Arriagada R, Pignon JP, Le Pechoux C, Group PM-aT. Postoperative radiotherapy for non-small cell lung cancer. *Cochrane Database Syst Rev*. 2016;10:CD002142. Epub 2016/11/02. doi: 10.1002/14651858.CD002142.pub4. PubMed PMID: 27727451.
 22. Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials. *Biometrical journal Biometrische Zeitschrift*. 2016;58(1):104-32. Epub 2015/02/17. doi: 10.1002/bimj.201400049. PubMed PMID: 25682941.
 23. Buzyn A, Blay JY, Hoog-Labouret N, Jimenez M, Nowak F, Deley MC, Pérol D, Cailliot C, Raynaud J, Vassal G. Equal access to innovative therapies and precision cancer care. *Nat Rev Clin Oncol*. 2016;13:385-93. PubMed PMID: 27000960.
 24. Castelnau-Marchand P, Levy A, Moya-Plana A, Mirghani H, Nguyen F, Del Campo ER, Janot F, Kolb F, Ferrand FR, Temam S, Blanchard P, Tao Y. Sinonasal squamous cell carcinoma without clinical lymph node involvement : Which neck management is best? *Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]*. 2016;192(8):537-44. Epub 2016/06/22. doi: 10.1007/s00066-016-0997-5. PubMed PMID: 27323752.
 25. Chargari C, Mazon R, Dunant A, Gouy S, Petit C, Maroun P, Uzan C, Annede P, Bentivegna E, Balleyguier C, Genestie C, Pautier P, Leary A, Lhomme C, Deutsch E, Morice P, Haie-Meder C. Impact of primary para-aortic lymphadenectomy on distant failure in locally advanced cervical cancer patients treated in the era of image-guided adaptive brachytherapy. *Clinical & experimental metastasis*. 2016;33(8):775-85. Epub 2016/08/18. doi: 10.1007/s10585-016-9817-7. PubMed PMID: 27530648.
 26. Charles C, Bungener C, Razavi D, Mateus C, Routier E, Lanoy E, Verschoore M, Robert C, Dauchy S. Impact of dermatologic adverse events induced by targeted therapies on quality of life. *Crit Rev Oncol Hematol*. 2016;101:158-68. PubMed PMID: 26995080.
 27. Charles C, Razavi D, Bungener C, Mateus C, Lanoy E, Verschoore M, Dauchy S, Robert C. Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study. *Clin Drug Investig*. 2016;36:235-42. PubMed PMID: 26754775.
 28. Chemama S, Bayar MA, Lanoy E, Ammari S, Stoclin A, Goéré D, Elias D, Raynard B, Antoun S. Sarcopenia is Associated with Chemotherapy Toxicity in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. *Ann Surg Oncol*. 2016;23:3891-8. PubMed PMID: 27352205.
 29. Chopra H, Arangalage D, Bouleti C, Zarka S, Fayard F, Chillon S, Laissy JP, Henry-Feugeas MC, Steg PG, Vahanian A, Ou P. Prognostic value of the infarct- and non-infarct like patterns and cardiovascular magnetic resonance parameters on long-term outcome of patients after acute myocarditis. *International journal of cardiology*. 2016;212:63-9. Epub 2016/04/02. doi: 10.1016/j.ijcard.2016.03.004. PubMed PMID: 27035605.
 30. Chouaid C, Borget I, Braun E, Bazil ML, Schaez D, Rémuzat C, Toumi M.

- French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends. *Target Oncol.* 2016;11:515-34. PubMed PMID: 26830301.
31. De Felice F, Blanchard P, Levy A, Nguyen F, Gorphe P, Janot F, Temam S, Tao Y. Treatment of squamous cell carcinoma of the posterior pharyngeal wall: Radiotherapy versus surgery. *Head Neck.* 2016;38 Suppl 1:E1722-9. Epub 2015/11/29. doi: 10.1002/hed.24307. PubMed PMID: 26613802.
 32. De Ruysscher D, Lueza B, Le Péchoux C, Johnson DH, O'Brien M, Murray N, Spiro S, Wang X, Takada M, Lebeau B, Blackstock W, Skarlos D, Baas P, Choy H, Price A, Seymour L, Arriagada R, Pignon JP. Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis. *Ann Oncol.* 2016;27:1818-28. PubMed PMID: 27436850.
 33. Delaloge S, Bonastre J, Borget I, Garbay JR, Fontenay R, Boinon D, Saghatchian M, Mathieu MC, Mazouni C, Rivera S, Uzan C, André F, Dromain C, Boyer B, Pistilli B, Azoulay S, Rimareix F, Bayou e-H, Sarfati B, Caron H, Ghouadni A, Leymarie N, Canale S, Mons M, Arfi-Rouche J, Arnedos M, Suci V, Vielh P, Balleyguier C. The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. *Eur J Cancer.* 2016;66:131-7. PubMed PMID: 27569041.
 34. Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, Bago-Horvath Z, Bane A, Bedri S, Brock J, Chmielik E, Christgen M, Colpaert C, Demaria S, Van den Eynden G, Floris G, Fox SB, Gao D, Ingold Heppner B, Kim SR, Kos Z, Kreipe HH, Lakhani SR, Penault-Llorca F, Pruneri G, Radosevic-Robin N, Rimm DL, Schnitt SJ, Sinn BV, Sinn P, Sirtaine N, O'Toole SA, Viale G, Van de Vijver K, de Wind R, von Minckwitz G, Klauschen F, Untch M, Fasching PA, Reimer T, Willard-Gallo K, Michiels S, Loi S, Salgado R. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. *Mod Pathol.* 2016;29:1155-64. PubMed PMID: 27363491.
 35. Desportes E, Wagner M, Kamal M, Salomon AV, Denizaut G, Pierron G, Rouleau E, Jouffroy T, Le Tourneau C, Paoletti X, Servois V. Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial. *Oncotarget.* 2016. Epub 2016/09/23. doi: 10.18632/oncotarget.12051. PubMed PMID: 27655703.
 36. Deutsch E, Haie-Meder C, Bayar MA, Mondini M, Laporte M, Mazon R, Adam J, Varga A, Vassal G, Magne N, Chargari C, Lanoy E, Pautier P, Levy A, Soria JC. Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients. *Oncotarget.* 2016;7(18):25549-57. Epub 2016/03/27. doi: 10.18632/oncotarget.8224. PubMed PMID: 27016411; PMCID: 5041925.
 37. Dourthe ME, Ternès N, Gajda D, Paci A, Dufour C, Benhamou E, Valteau-Couanet D. Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration. *Bone Marrow Transplant.* 2016;51:1265-7. PubMed PMID: 27111042.
 38. Doussau A, Georger B, Jimenez I, Paoletti X. Innovations for phase I dose-finding designs in pediatric oncology clinical trials. *Contemporary clinical trials.* 2016;47:217-27. Epub 2016/01/31. doi: 10.1016/j.cct.2016.01.009. PubMed

PMID: 26825023; PMCID: 4818190.

39. Ducreux M, Pignon JP. Bevacizumab versus anti-epidermal growth factor receptor in first-line metastatic colorectal cancer. A meta-analysis: The last building block? *European journal of cancer*. 2016;69:178-9. Epub 2016/11/12. doi: 10.1016/j.ejca.2016.10.001. PubMed PMID: 27835821.
40. Foulon S, Brennan B, Gaspar N, Dirksen U, Jeys L, Cassoni A, Claude L, Seddon B, Marec-Berard P, Whelan J, Paulussen M, Streitbuerger A, Oberlin O, Juergens H, Grimer R, Le Deley MC. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group. *European journal of cancer*. 2016;61:128-36. Epub 2016/05/14. doi: 10.1016/j.ejca.2016.03.075. PubMed PMID: 27176931.
41. Freyer G, Scotte F, Borget I, Bruyas A, Vainchtock A, Chouaid C. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database]. *Bull Cancer*. 2016;103:552-60. PubMed PMID: 27233367.
42. Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, O'Brien C, Walter K, Huw LY, Criscitiello C, Laios I, Jose V, Brown DN, Rothé F, Maetens M, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart MJ, Michiels S, Lackner MR, Sotiriou C, Loi S. Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. *Ann Oncol*. 2016;27:1860-6. PubMed PMID: 27672107.
43. Gault N, Castaneda-Sanabria J, Guillo S, Foulon S, Tubach F. Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review. *Pharmacoepidemiol Drug Saf*. 2016;25(4):372-7. Epub 2016/01/20. doi: 10.1002/pds.3955. PubMed PMID: 26781227.
44. Gault N, Castañeda-Sanabria J, Guillo S, Foulon S, Tubach F. Underuse of self-controlled designs in pharmacoepidemiology in electronic healthcare databases: a systematic review. *Pharmacoepidemiol Drug Saf*. 2016;25:372-7. PubMed PMID: 26781227.
45. Gizzi M, Oberic L, Massard C, Poterie A, Gwenael LT, Lorient Y, Albiges L, Baciarello G, Michels J, Bossi A, Blanchard P, Escudier B, Fizazi K. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. *European journal of cancer*. 2016;69:151-7. Epub 2016/11/09. doi: 10.1016/j.ejca.2016.10.003. PubMed PMID: 27821318.
46. Gorphe P, Blanchard P, Moriniere S, Fakhry N. Treatment strategies in early-stage oropharyngeal squamous cell carcinoma: a French national survey. *Eur Arch Otorhinolaryngol*. 2016;273(8):2201-7. Epub 2015/08/09. doi: 10.1007/s00405-015-3744-0. PubMed PMID: 26253428.
47. Gorphe P, Matias M, Even C, Ferte C, Bidault F, Garcia G, Temam S, Nguyen F, Blanchard P, Tao Y, Janot F. Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma. *Anticancer research*. 2016;36(12):6625-30. Epub 2016/12/07. PubMed PMID: 27919993.
48. Gorphe P, Matias M, Moya-Plana A, Tabarino F, Blanchard P, Tao Y, Janot F, Temam S. Results and Survival of Locally Advanced AJCC 7th Edition T4a Laryngeal Squamous Cell Carcinoma Treated with Primary Total Laryngectomy and Postoperative Radiotherapy. *Annals of surgical oncology*. 2016;23(8):2596-601. Epub 2016/04/02. doi: 10.1245/s10434-016-5217-0.

- PubMed PMID: 27034080.
49. Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, Quenet F, Bereder JM, Le Deley MC, Morice P. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. *Gynecol Oncol.* 2016;142:237-42. PubMed PMID: 27246305.
 50. Gunn GB, Blanchard P, Garden AS, Zhu XR, Fuller CD, Mohamed AS, Morrison WH, Phan J, Beadle BM, Skinner HD, Sturgis EM, Kies MS, Hutcheson KA, Rosenthal DI, Mohan R, Gillin MT, Frank SJ. Clinical Outcomes and Patterns of Disease Recurrence After Intensity Modulated Proton Therapy for Oropharyngeal Squamous Carcinoma. *International journal of radiation oncology, biology, physics.* 2016;95(1):360-7. Epub 2016/04/17. doi: 10.1016/j.ijrobp.2016.02.021. PubMed PMID: 27084653.
 51. Guyot P, Ades AE, Beasley M, Lueza B, Pignon JP, Welton NJ. Extrapolation of Survival Curves from Cancer Trials Using External Information. *Med Decis Making.* 2016. PubMed PMID: 27681990.
 52. Haddy N, Diallo S, El-Fayech C, Schwartz B, Pein F, Hawkins M, Veres C, Oberlin O, Guibout C, Pacquement H, Munzer M, N'Guyen TD, Bondiau PY, Berchery D, Laprie A, Scarabin PY, Jouven X, Bridier A, Koscielny S, Deutsch E, Diallo I, de Vathaire F. Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study. *Circulation.* 2016;133:31-8. PubMed PMID: 26487757.
 53. Hartl DM, Breuskin I, Mirghani H, Berdelou A, Déandréis D, Pottier E, Borget I, Schlumberger M, Leboulleux S. Anatomic Variability of the Upper Mediastinal Lymph Node Level VII. *World J Surg.* 2016;40:1899-903. PubMed PMID: 27075985.
 54. Heinze G, Michiels S, Posch M. Preface. *Stat Med.* 2016;35:965. PubMed PMID: 26932123.
 55. Helisse C, Biondani P, Roquet F, Lanoy E, Mir O, Varga A, Massard C, Gazzah A, Ribrag V, Bahleda R, Postel-Vinay S, Angevin E, Deutsch E, Soria JC, Hollebecque A. Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience. *Int J Cancer.* 2016;138:875-80. PubMed PMID: 26370299.
 56. Hollebecque A, Lanoy E, Troallen F, Soulat-Dufour L, Massard C, Bahleda R, Varga A, Gazzah A, Postel-Vinay S, Ribrag V, Deutsch E, Angevin E, Boccaro F, Cohen A, Soria JC, Ederhy S. Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. *Int J Cardiol.* 2016;214:364-9. PubMed PMID: 27085130.
 57. Holliday EB, Kocak-Uzel E, Feng L, Thaker NG, Blanchard P, Rosenthal DI, Gunn GB, Garden AS, Frank SJ. Dosimetric advantages of intensity-modulated proton therapy for oropharyngeal cancer compared with intensity-modulated radiation: A case-matched control analysis. *Medical dosimetry : official journal of the American Association of Medical Dosimetrists.* 2016;41(3):189-94. Epub 2016/05/10. doi: 10.1016/j.meddos.2016.01.002. PubMed PMID: 27158021.
 58. Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H, Viollet R, Thomas M, Roy S, Benannoune N, Tomasic G, Soria JC, Champiat S, Texier M, Lanoy E, Robert C. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. *JAMA*

- Dermatol. 2016;152:45-51. PubMed PMID: 26501224.
59. Ignatiadis M, Azim HA, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell'Orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart M, Michiels S, Sotiriou C. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. *JAMA Oncol.* 2016;2:217-24. PubMed PMID: 26633571.
 60. Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, D'Hondt V, De Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart M, Awada A. Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. *PLoS ONE.* 2016;11:e0154009. PubMed PMID: 27454930.
 61. Jovelet C, Ileana E, Le Deley MC, Motté N, Rosellini S, Romero A, Lefebvre C, Pedrero M, Pata-Merci N, Droin N, Deloger M, Massard C, Hollebecque A, Ferté C, Boichard A, Postel-Vinay S, Ngo-Camus M, De Baere T, Vielh P, Scoazec JY, Vassal G, Eggermont A, André F, Soria JC, Lacroix L. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial. *Clin Cancer Res.* 2016;22:2960-8. PubMed PMID: 26758560.
 62. Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JV, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GH, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS. The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. *Clin Sarcoma Res.* 2016;6:3. PubMed PMID: 27315524.
 63. Kempf E, Lemoine N, Tergemina-Clain G, Turpin A, Postel-Vinay S, Lanoy E, Soria JC, Massard C, Hollebecque A. A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials. *PLoS ONE.* 2016;11:e0154895. PubMed PMID: 27149667.
 64. Król A, Ferrer L, Pignon JP, Proust-Lima C, Ducreux M, Bouché O, Michiels S, Rondeau V. Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the FFCD 2000-05 trial. *Biometrics.* 2016;72:907-16. PubMed PMID: 26890381.
 65. Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, Al Ghuzlan A, Hartl D, Blanchard P, Terroir M, Deandreis D, Schlumberger M, Baudin E, Leboulleux S. Antiangiogenic Tyrosine Kinase Inhibitors: Occurrence and Risk Factors of Hemoptysis in Refractory Thyroid Cancer. *The Journal of clinical endocrinology and metabolism.* 2016;101(7):2733-41. Epub 2016/04/16. doi: 10.1210/jc.2015-4391. PubMed PMID: 27082933.
 66. Lassau N, Coiffier B, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L,

- Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Benatsou B, Bonastre J, Koscielny S. Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO*. 2016;27(10):1922-8. Epub 2016/08/10. doi: 10.1093/annonc/mdw280. PubMed PMID: 27502701; PMCID: 5035788.
67. Lazimi J, Dagouat JB, Abbas R, Oubaya N, Fagnou B, Hiegel C, Raynaud-Simon A. Prévalence de la fragilité, de la sarcopénie et de la dénutrition dans une population âgée vivant à domicile et participant à des séances d'activité physique adaptée. Évolution des paramètres fonctionnels et nutritionnels après 4 mois. *Nutrition Clinique et Métabolisme*. 2016;30(3):223. doi: <http://dx.doi.org/10.1016/j.nupar.2016.09.004>.
68. Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, Rouleau E, Vincent-Salomon A, Servant N, Alt M, Rouzier R, Paoletti X, Delattre O, Bieche I. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. *Journal of the National Cancer Institute*. 2016;108(4). Epub 2015/11/26. doi: 10.1093/jnci/djv362. PubMed PMID: 26598514; PMCID: 4830395.
69. Lefebvre A, Manoha C, Bour JB, Abbas R, Fournel I, Tiv M, Pothier P, Astruc K, Aho-Glele LS. Human metapneumovirus in patients hospitalized with acute respiratory infections: A meta-analysis. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology*. 2016;81:68-77. Epub 2016/06/24. doi: 10.1016/j.jcv.2016.05.015. PubMed PMID: 27337518.
70. Levy A, Bardet E, Lacas B, Pignon JP, Adam J, Lacroix L, Artignan X, Verrelle P, Le Pechoux C. A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. *Oncotarget*. 2016. Epub 2016/10/21. doi: 10.18632/oncotarget.12741. PubMed PMID: 27764781.
71. Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart MJ, Dowsett M, Michiels S, Leyland-Jones B. Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial. *JAMA Oncol*. 2016;2:1040-7. PubMed PMID: 27100299.
72. Lueza B, Lacas B, Pignon JP, Paoletti X. [New applications for individual participant data meta-analyses of randomized trials]. *Bull Cancer*. 2016. Epub 2016/12/03. doi: 10.1016/j.bulcan.2016.10.024. PubMed PMID: 27908441.
73. Lueza B, Mauguen A, Pignon JP, Rivero-Arias O, Bonastre J. Difference in Restricted Mean Survival Time for Cost-Effectiveness Analysis Using Individual Patient Data Meta-Analysis: Evidence from a Case Study. *PLoS ONE*. 2016;11:e0150032. PubMed PMID: 26960150.
74. Lueza B, Rotolo F, Bonastre J, Pignon JP, Michiels S. Erratum to: Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. *BMC Med Res Methodol*. 2016;16:71. PubMed PMID: 27306030.
75. Lueza B, Rotolo F, Bonastre J, Pignon JP, Michiels S. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis. *BMC Med Res Methodol*. 2016;16:37. PubMed PMID: 27025706.

76. Ma X, Le Teuff G, Lacas B, Tsao MS, Graziano S, Pignon JP, Douillard JY, Le Chevalier T, Seymour L, Filipits M, Pirker R, Jänne PA, Shepherd FA, Brambilla E, Soria JC, Hainaut P. Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis. *J Thorac Oncol*. 2016;11:850-61. PubMed PMID: 26899019.
77. Maingon P, Blanchard P, Bidault F, Calmels L. [Radiotherapy for nasopharyngeal carcinoma]. *Cancer Radiother*. 2016;20 Suppl:S104-9. Epub 2016/08/16. doi: 10.1016/j.canrad.2016.07.031. PubMed PMID: 27523419.
78. Marguet S, Mazouni C, Ramaekers BL, Dunant A, Kates R, Jacobs VR, Joore MA, Harbeck N, Bonastre J. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer. *Eur J Cancer*. 2016;63:168-79. PubMed PMID: 27322916.
79. Martelli N, Hansen P, van den Brink H, Boudard A, Cordonnier AL, Devaux C, Pineau J, Prognon P, Borget I. Combining multi-criteria decision analysis and mini-health technology assessment: A funding decision-support tool for medical devices in a university hospital setting. *J Biomed Inform*. 2016;59:201-8. PubMed PMID: 26705065.
80. Martelli N, Serrano C, van den Brink H, Pineau J, Prognon P, Borget I, El Batti S. Advantages and disadvantages of 3-dimensional printing in surgery: A systematic review. *Surgery*. 2016;159:1485-500. PubMed PMID: 26832986.
81. Martelli N, van den Brink H, Borget I. New French Coverage with Evidence Development for Innovative Medical Devices: Improvements and Unresolved Issues. *Value Health*. 2016;19:17-9. PubMed PMID: 26797231.
82. Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. *J Crohns Colitis*. 2016;10:395-401. PubMed PMID: 26783344.
83. Massard C, Oulhen M, Le Moulec S, Auger N, Foulon S, Abou-Lovergne A, Billiot F, Valent A, Marty V, Lorient Y, Fizazi K, Vielh P, Farace F. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: a report from the PETRUS prospective study. *Oncotarget*. 2016. Epub 2016/07/09. doi: 10.18632/oncotarget.10396. PubMed PMID: 27391263.
84. Mazon R, Petit C, Rivin E, Limkin E, Dumas I, Maroun P, Annede P, Martinetti F, Seisen T, Lefkopoulos D, Chargari C, Haie-Meder C. 45 or 50 Gy, Which is the Optimal Radiotherapy Pelvic Dose in Locally Advanced Cervical Cancer in the Perspective of Reaching Magnetic Resonance Image-guided Adaptive Brachytherapy Planning Aims? *Clinical oncology*. 2016;28(3):171-7. Epub 2015/11/09. doi: 10.1016/j.clon.2015.10.008. PubMed PMID: 26547694.
85. McKeever MR, Sio TT, Gunn GB, Holliday EB, Blanchard P, Kies MS, Weber RS, Frank SJ. Reduced acute toxicity and improved efficacy from intensity-modulated proton therapy (IMPT) for the management of head and neck cancer. *Chinese clinical oncology*. 2016;5(4):54. Epub 2016/08/11. doi: 10.21037/cco.2016.07.03. PubMed PMID: 27506808.
86. Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, Chautard E, Auboeuf D, Fenaux P, Braun T, Itzykson R, de Botton S, Quesnel B, Commes T, Jourdan E, Vainchenker W, Bernard O, Pata-Merci N, Solier S, Gayevskiy

- V, Dinger ME, Cowley MJ, Selimoglu-Buet D, Meyer V, Artiguenave F, Deleuze JF, Preudhomme C, Stratton MR, Alexandrov LB, Padron E, Ogawa S, Koscielny S, Figueroa M, Solary E. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. *Nat Commun.* 2016;7:10767. PubMed PMID: 26908133.
87. Michiels S, Pugliano L, Marguet S, Grun D, Barinoff J, Cameron D, Cobleigh M, Di Leo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekljudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. *Ann Oncol.* 2016;27:1029-34. PubMed PMID: 26961151.
88. Michiels S, Ternès N, Rotolo F. Statistical controversies in clinical research: prognostic gene signatures are not (yet) useful in clinical practice. *Ann Oncol.* 2016. PubMed PMID: 27634691.
89. Mirghani H, Casiraghi O, Guerlain J, Amen F, He MX, Ma XJ, Luo Y, Mourareau C, Drusch F, Lakdhar AB, Melkane A, St Guily L, Badoual C, Scoazec JY, Borget I, Auperin A, Dalstein V, Vielh P. Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test. *Oral oncology.* 2016;62:101-8. Epub 2016/11/21. doi: 10.1016/j.oraloncology.2016.10.009. PubMed PMID: 27865361.
90. Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Loi S, Smyth MJ. Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells. *Cancer research.* 2016;76(2):264-74. Epub 2016/01/09. doi: 10.1158/0008-5472.CAN-15-1567. PubMed PMID: 26744522.
91. Ou D, Levy A, Blanchard P, Nguyen F, Garberis I, Casiraghi O, Scoazec JY, Janot F, Temam S, Deutsch E, Tao Y. Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role? *Oral oncology.* 2016;59:50-7. Epub 2016/07/18. doi: 10.1016/j.oraloncology.2016.05.019. PubMed PMID: 27424182.
92. Ouldamer L, Bonastre J, Brunet-Houdard S, Body G, Giraudeau B, Caille A. Dead space closure with quilting suture versus conventional closure with drainage for the prevention of seroma after mastectomy for breast cancer (QUISERMAS): protocol for a multicentre randomised controlled trial. *BMJ Open.* 2016;6(4):e009903. Epub 2016/04/06. doi: 10.1136/bmjopen-2015-009903. PubMed PMID: 27044574; PMCID: 4823448.
93. Pages A, Foulon S, Zou Z, Lacroix L, Lemare F, de Baere T, Massard C, Soria JC, Bonastre J. The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial. *Genetics in medicine : official journal of the American College of Medical Genetics.* 2016. Epub 2016/12/03. doi: 10.1038/gim.2016.174. PubMed PMID: 27906201.
94. Paoletti X, Rotolo F, Michiels S. [Not Available]. *Bull Cancer.* 2016;103(6 Suppl 1):S63-70. Epub 2016/08/09. doi: 10.1016/S0007-4551(16)30147-3. PubMed PMID: 27494976.
95. Peeler CR, Mirkovic D, Titt U, Blanchard P, Gunther JR, Mahajan A, Mohan R, Grosshans DR. Clinical evidence of variable proton biological effectiveness in pediatric patients treated for ependymoma. *Radiother Oncol.* 2016. Epub

- 2016/11/20. doi: 10.1016/j.radonc.2016.11.001. PubMed PMID: 27863964.
96. Petit C, Dumas I, Chargari C, Martinetti F, Maroun P, Doyeux K, Tailleur A, Haie-Meder C, Mazon R. MRI-guided brachytherapy in locally advanced cervical cancer: Small bowel [Formula: see text] and [Formula: see text] are not predictive of late morbidity. *Brachytherapy*. 2016;15(4):463-70. Epub 2016/05/18. doi: 10.1016/j.brachy.2016.04.004. PubMed PMID: 27180130.
97. Piperno-Neumann S, Le Deley MC, Redini F, Pacquement H, Marec-Berard P, Petit P, Brisse H, Lervat C, Gentet JC, Entz-Werle N, Italiano A, Corradini N, Bompas E, Penel N, Tabone MD, Gomez-Brouchet A, Guinebretiere JM, Mascard E, Gouin F, Chevance A, Bonnet N, Blay JY, Brugieres L, Sarcoma Group of U, French Society of Pediatric O, French Sarcoma G. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. *The Lancet Oncology*. 2016;17(8):1070-80. Epub 2016/06/22. doi: 10.1016/S1470-2045(16)30096-1. PubMed PMID: 27324280.
98. Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. *Ann Oncol*. 2016;27(2):214-24. Epub 2015/11/19. doi: 10.1093/annonc/mdv550. PubMed PMID: 26578728.
99. Proust-Houdemont S, Pasqualini C, Blanchard P, Dufour C, Benhamou E, Goma G, Semeraro M, Raquin MA, Hartmann O, Valteau-Couanet D. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution. *Bone marrow transplantation*. 2016;51(8):1076-81. Epub 2016/04/05. doi: 10.1038/bmt.2016.75. PubMed PMID: 27042850.
100. Randon M, Liang H, Abbas R, Michee S, Denoyer A, Baudouin C, Labbe A. [A new classification for meibomian gland diseases with in vivo confocal microscopy]. *Journal francais d'ophtalmologie*. 2016;39(3):239-47. Epub 2016/02/21. doi: 10.1016/j.jfo.2015.07.015. PubMed PMID: 26896195.
101. Regairaz M, Munier F, Sartelet H, Castaing M, Marty V, Renauleaud C, Doux C, Delbe J, Courty J, Fabre M, Ohta S, Viehl P, Michiels S, Valteau-Couanet D, Vassal G. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma. *Am J Pathol*. 2016;186(2):435-45. Epub 2015/12/22. doi: 10.1016/j.ajpath.2015.10.016. PubMed PMID: 26687816.
102. Remon J, Bonastre J, Besse B. The 5000% case: a glimpse into the financial issue of lung cancer treatment. *Eur Respir J*. 2016;47(5):1331-3. Epub 2016/05/02. doi: 10.1183/13993003.00548-2016. PubMed PMID: 27132267.
103. Ribassin-Majed L, Marquet S, Lee AW, Ng WT, Ma J, Chan AT, Huang PY, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Bourhis J, Pignon JP, Blanchard P. What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2016;JCO2016674119. Epub 2016/12/06. PubMed PMID: 27918720.
104. Ribassin-Majed L, Pignon JP, Michiels S, Blanchard P. [Network meta-analyses: Interest and limits in oncology]. *Bull Cancer*. 2016;103(3):289-93. Epub 2016/02/27. doi: 10.1016/j.bulcan.2016.01.003. PubMed PMID: 26917469.
105. Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Guill S, Ojeda-

- Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clement C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2016;387(10036):2402-11. Epub 2016/04/16. doi: 10.1016/S0140-6736(15)01317-3. PubMed PMID: 27080498.
106. Rococo E, Mazouni C, Or Z, Mobillion V, Koon Sun Pat M, Bonastre J. Variation in rates of breast cancer surgery: A national analysis based on French Hospital Episode Statistics. *Eur J Surg Oncol*. 2016;42(1):51-8. Epub 2015/10/23. doi: 10.1016/j.ejso.2015.09.020. PubMed PMID: 26490007.
107. Rodriguez C, Suci V, Poterie A, Lacroix L, Miran I, Boichard A, Delalogue S, Deneuve J, Azoulay S, Mathieu MC, Valent A, Michiels S, Arnedos M, Vielh P. Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients. *Mol Oncol*. 2016;10(9):1430-6. Epub 2016/08/25. doi: 10.1016/j.molonc.2016.07.009. PubMed PMID: 27555543. (Co-dernier auteur)
108. Rotolo F, Rondeau V, Legrand C. Incorporation of nested frailties into semiparametric multi-state models. *Stat Med*. 2016;35(4):609-21. Epub 2015/09/19. doi: 10.1002/sim.6734. PubMed PMID: 26381148.
109. Rozet F, Roupret M, Hennequin C, Massard C, Blanchard P, Le Moulec S. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2016;26(13):778-9. Epub 2016/12/15. doi: 10.1016/j.purol.2016.07.221. PubMed PMID: 27969314.
110. Saghatchian M, Fadoukhair Z, Hofert K, Lanoy E, Mathieu MC, Mazouni C, Delalogue S. Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries. *Breast J*. 2016;22(1):96-100. Epub 2015/10/30. doi: 10.1111/tbj.12525. PubMed PMID: 26511594.
111. Singhal SK, Usmani N, Michiels S, Metzger-Filho O, Saini KS, Kovalchuk O, Parliament M. Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data. *Oncotarget*. 2016;7(3):3002-17. Epub 2015/12/15. doi: 10.18632/oncotarget.6503. PubMed PMID: 26657508; PMCID: 4823086.
112. Sio TT, Lin HK, Shi Q, Gunn GB, Cleeland CS, Lee JJ, Hernandez M, Blanchard P, Thaker NG, Phan J, Rosenthal DI, Garden AS, Morrison WH, Fuller CD, Mendoza TR, Mohan R, Wang XS, Frank SJ. Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. *International journal of radiation oncology, biology, physics*. 2016;95(4):1107-14. Epub 2016/06/30. doi: 10.1016/j.ijrobp.2016.02.044. PubMed PMID: 27354125.
113. Tacher V, Le Deley MC, Hollebecque A, Deschamps F, Vielh P, Hakime A, Ileana E, Abedi-Ardekani B, Charpy C, Massard C, Rosellini S, Gajda D, Celebic A, Ferte C, Ngo-Camus M, Gouisse S, Koubi-Pick V, Andre F, Vassal G, Deandreis D, Lacroix L, Soria JC, De Baere T. Factors associated with success of image-guided tumour biopsies: Results from a prospective molecular triage study (MOSCATO-01). *European journal of cancer*. 2016;59:79-89. Epub 2016/03/28. doi: 10.1016/j.ejca.2016.02.006. PubMed PMID: 27017289.
114. Ternès N, Rotolo F, Heinze G, Michiels S. Identification of biomarker-

by-treatment interactions in randomized clinical trials with survival outcomes and high-dimensional spaces. *Biometrical journal Biometrische Zeitschrift*. 2016. Epub 2016/11/20. doi: 10.1002/bimj.201500234. PubMed PMID: 27862181.

115. Ternès N, Rotolo F, Michiels S. Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models. *Stat Med*. 2016;35(15):2561-73. Epub 2016/03/13. doi: 10.1002/sim.6927. PubMed PMID: 26970107.
116. Terroir M, Borget I, Bidault F, Ricard M, Deschamps F, Hartl D, Tselikas L, Dercle L, Lumbroso J, Baudin E, Berdelou A, Deandreis D, Schlumberger M, Leboulleux S. The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging*. 2016. Epub 2016/11/01. doi: 10.1007/s00259-016-3551-x. PubMed PMID: 27796544.
117. Xu P, Min Y, Blanchard P, Feng M, Zhang P, Luo Y, Fan Z, Lang J. Incidence of small lymph node metastases in patients with nasopharyngeal carcinoma: Clinical implications for prognosis and treatment. *Head Neck*. 2016. Epub 2016/09/15. doi: 10.1002/hed.24586. PubMed PMID: 27627795.
118. Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, Kammerer SF, Rioux-Leclerc N, Hasmmim M, Ferlicot S, Baud V, Mejean A, Mole DR, Richard S, Eggermont AM, Albiges L, Mami-Chouaib F, Escudier B, Chouaib S. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. *Eur Urol*. 2016 Oct;70(4):623-632. doi: 10.1016/j.eururo.2015.11.029.
119. Jaillette, E ; Girault, C ; Brunin, G ; Zerimech, F ; Chiche, A ; Broucqsaault-Dedrie, C & al. French Intensive Care Society, International congress - Réanimation 2016. *Ann Intensive Care*. 2016;6:50. PubMed PMID: 27316915.
120. van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem GE, van den Oord J, Feunteun J, Spatz A. The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene. *Sci Transl Med*. 2016 Dec 14;8(369):369ra177.